Crafting a robust business model for orphan drug development.
作者信息
Philippidis Alex
出版信息
Hum Gene Ther. 2011 Jul;22(7):781-3. doi: 10.1089/hum.2011.2511.
PMID:21756074
Abstract
摘要
相似文献
1
Crafting a robust business model for orphan drug development.为罕见病药物研发打造强大的商业模式。
Hum Gene Ther. 2011 Jul;22(7):781-3. doi: 10.1089/hum.2011.2511.
2
Raising orphans: how clinical development programs of drugs for rare and common diseases are different.孤儿药的研发：罕见病和常见病药物的临床开发项目有何不同。
Clin Pharmacol Ther. 2012 Aug;92(2):262-4. doi: 10.1038/clpt.2012.87. Epub 2012 Jun 27.
3
Orphan drug development: an economically viable strategy for biopharma R&D.孤儿药开发：生物制药研发的经济可行策略。
Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005. Epub 2012 Feb 17.
4
Law and research could add up to profitable niche drugs.法律与研究相结合有望催生有利可图的小众药物。
Nature. 2007 Apr 19;446(7138):856. doi: 10.1038/446856b.
5
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.超罕见病和罕见病患者/家长在药物研发中的多面角色。
Drug Discov Today. 2013 Nov;18(21-22):1043-51. doi: 10.1016/j.drudis.2013.08.006. Epub 2013 Aug 19.
6
Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.罕见（孤儿）病药物：一项关于税收激励措施的调查与提议
Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14.
7
[Orphan drugs: drugs for rare diseases].[孤儿药：用于罕见病的药物]
Dtsch Med Wochenschr. 2010 May;135(18):p17.
8
Quantitative analysis to guide orphan drug development.定量分析指导孤儿药开发。
Clin Pharmacol Ther. 2012 Aug;92(2):258-61. doi: 10.1038/clpt.2012.80. Epub 2012 Jun 27.
9
New models for pharmaceutical innovation in low-income countries.低收入国家药物创新的新模式。
Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.
10
Big pharma moves from 'blockbusters' to 'niche busters'.大型制药公司从“重磅炸弹”药物转向“利基杀手”药物。
Nat Med. 2010 Aug;16(8):837. doi: 10.1038/nm0810-837a.
Zotero 插件